Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Systemic lupus erythematosus

Hydroxychloroquine dose: balancing toxicity and SLE flare risk

Nature Reviews Rheumatology volume 19, pages 6–7 (2023)Cite this article

Subjects

Contemporary guidelines for the management of systemic lupus erythematosus (SLE) recommend prescribing hydroxychloroquine dosages of 5 mg/kg per day or lower to minimize toxicity. However, new evidence raises serious concerns about the risk of SLE flare associated with such doses. How do the benefits and risks of this controversial recommendation balance out?

Refers to Jorge, A. M. et al. Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares. JAMA 328, 1458–1460 (2022).

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736–745 (2019).

    Article  CAS  Google Scholar 

  2. Costedoat-Chalumeau, N., Isenberg, D. & Petri, M. Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al. Ann. Rheum. Dis. 79, e90 (2020).

    Article  Google Scholar 

  3. Jorge, A. M. et al. Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares. JAMA 328, 1458–1460 (2022).

    Article  CAS  Google Scholar 

  4. Almeida-Brasil, C. C. et al. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann. Rheum. Dis. 81, 370–378 (2022).

    Article  CAS  Google Scholar 

  5. Melles, R. B. & Marmor, M. F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132, 1453–1460 (2014).

    Article  Google Scholar 

  6. Petri, M., Konig, M. F., Li, J. & Goldman, D. W. Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol. 73, 997–1004 (2021).

    Article  CAS  Google Scholar 

  7. Feldman, C. H. et al. Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin. Arthritis Rheum. 48, 205–213 (2018).

    Article  Google Scholar 

  8. Marmor, M. F. et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 123, 1386–1394 (2016).

    Article  Google Scholar 

  9. Lenfant, T. et al. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatology (Oxford) 59, 3807–3816 (2020).

    Article  CAS  Google Scholar 

  10. Costedoat-Chalumeau, N. et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin. Pharmacol. Ther. 103, 1074–1082 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Centre de Référence Maladies Auto-Immunes et Systémiques Rares d’Ile de France, Cochin Hospital, AP-HP, Paris, France

    Tiphaine Lenfant & Nathalie Costedoat-Chalumeau

  2. Center for Epidemiology and Statistics, Université Paris Cité (CRESS), INSERM U1153, Paris, France

    Tiphaine Lenfant & Nathalie Costedoat-Chalumeau

Authors
  1. Tiphaine Lenfant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathalie Costedoat-Chalumeau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathalie Costedoat-Chalumeau.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lenfant, T., Costedoat-Chalumeau, N. Hydroxychloroquine dose: balancing toxicity and SLE flare risk. Nat Rev Rheumatol 19, 6–7 (2023). https://doi.org/10.1038/s41584-022-00868-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-022-00868-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing